Potential solutions for manufacture of CAR T cells in cancer immunotherapy
CAR T cell therapy is an effective cancer treatment, but biological and manufacturing
hurdles hamper its broad breakthrough. Although the first step towards automated …
hurdles hamper its broad breakthrough. Although the first step towards automated …
Best practices and considerations for clinical pharmacology and pharmacometric aspects for optimal development of CAR‐T and TCR‐T cell therapies: an industry …
With the promise of a potentially “single dose curative” paradigm, CAR‐T cell therapies have
brought a paradigm shift in the treatment and management of hematological malignancies …
brought a paradigm shift in the treatment and management of hematological malignancies …
Price and prejudice? The value of chimeric antigen receptor (CAR) T-cell therapy
G Choi, G Shin, SJ Bae - … Journal of Environmental Research and Public …, 2022 - mdpi.com
Although chimeric antigen receptor (CAR) T-cell therapy has shown a high response rate in
lymphoma patients, its cost-effectiveness is controversial due to the high price and …
lymphoma patients, its cost-effectiveness is controversial due to the high price and …
AAV-mediated delivery of a Slee** Beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells
Engineering cells for adoptive therapy requires overcoming limitations in cell viability and, in
the efficiency of transgene delivery, the duration of transgene expression and the stability of …
the efficiency of transgene delivery, the duration of transgene expression and the stability of …
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells
AZ Gad, JS Morris, L Godret-Miertschin… - Science …, 2025 - science.org
Chimeric antigen receptor T cells (CART) targeting CD19 through CD28. ζ signaling induce
rapid lysis of leukemic blasts, contrasting with persistent tumor control exhibited by 4-1BB. ζ …
rapid lysis of leukemic blasts, contrasting with persistent tumor control exhibited by 4-1BB. ζ …
Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer
J Chen, J Hu, L Gu, F Ji, F Zhang, M Zhang, J Li… - Cancer Immunology …, 2023 - Springer
Recently, chimeric antigen receptor T cell (CAR-T) therapy has received increasing attention
as an adoptive cellular immunotherapy that targets tumors. However, numerous challenges …
as an adoptive cellular immunotherapy that targets tumors. However, numerous challenges …
Towards evidence-based response criteria for cancer immunotherapy
Early detection of immunotherapy-induced tumor response is of major benefit for patients but
can be complicated by therapy-induced pseudoprogression. A consensus guideline …
can be complicated by therapy-induced pseudoprogression. A consensus guideline …
Better by design: what to expect from novel CAR-engineered cell therapies?
V Luginbuehl, E Abraham, K Kovar, R Flaaten… - Biotechnology …, 2022 - Elsevier
Chimeric antigen receptor (CAR) technology, and CAR-T cells in particular, have emerged
as a new and powerful tool in cancer immunotherapy since demonstrating efficacy against …
as a new and powerful tool in cancer immunotherapy since demonstrating efficacy against …
Cellular therapy updates in B-cell lymphoma: the state of the CAR-T
ZD Crees, A Ghobadi - Cancers, 2021 - mdpi.com
Simple Summary B-cell lymphomas are the most commonly occurring blood cancer and the
second leading cause of cancer-related death among blood cancers. Chemotherapy and …
second leading cause of cancer-related death among blood cancers. Chemotherapy and …